POLE4

Across TCGA pan-cancer cohorts, POLE4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated POLE4 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher POLE4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated POLE4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where POLE4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.637	1.000	.009	13	view →
LSCC	DFS	Tertile	II,III,IV	0.867	0.473	.012	5	view →
HNSC	OS	Quartile	All	0.786	0.912	.034	3	view →
CCRCC	DFS	Median	All	0.881	0.727	.024	2	view →
PDAC	OS	Quartile	III,IV	0.864	0.482	.013	2	view →
GBM	OS	Median	All	0.640	0.417	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

POLE4–LUAD (OS)

Open the LUAD breakdown →